BACKGROUND: Progressive lung disease is the main cause of clinical deterioration and mortality in cystic fibrosis (CF) patients. Being able to assess the effectiveness of interventions is very significant. OBJECTIVES: To assess the response to intravenous (IV) treatment among CF patients, using forced expired volume in 1(st) second (FEV1) and Lung Clearance Index (LCI) as outcome measures and to compare the effect of IV treatment on lung function and LCI between CF children being treated on a regular basis, or in case of a pulmonary exacerbation. SUBJECTS AND METHODS: Thirty-two CF patients (15 males) with mean age 9.90 (range: 2-23) years, performed spirometry and multiple breath washout (MBW) before and one month after IV antibiotic treatment. Nineteen patients received a course of elective treatment (group A) and 13 received IV antibiotic regimens for an acute exacerbation (group B). RESULTS: Statistically significant differences after treatment were seen in LCI (p≤0.001), and Forced Expiratory Flow (FEF) z-scores (p<0.05). FEV1 did not change significantly after drug intervention. Dividing patients into two groups, only LCI showed significant change (p<0.05), when treatment was administered on a regular basis. Patients being treated for an acute pulmonary exacerbation showed significant improvement in most of the lung function parameters: LCI (p=0.0001), FEV1% (p=0.05), FEV1 z-score (p=0.033) and FEF25-75 (p=0.046). The mean LCI difference was significantly greater in group B compared to group A (p=0.001). CONCLUSION: LCI is more sensitive marker than FEV1 to assess the effect of IV antibiotic treatment among CF children. IV antibiotics are more effective on lung function parameters, when they are administered for an acute exacerbation, than when they are given on a regular basis. Hippokratia 2015, 19 (1): 47-52.
BACKGROUND: Progressive lung disease is the main cause of clinical deterioration and mortality in cystic fibrosis (CF) patients. Being able to assess the effectiveness of interventions is very significant. OBJECTIVES: To assess the response to intravenous (IV) treatment among CFpatients, using forced expired volume in 1(st) second (FEV1) and Lung Clearance Index (LCI) as outcome measures and to compare the effect of IV treatment on lung function and LCI between CFchildren being treated on a regular basis, or in case of a pulmonary exacerbation. SUBJECTS AND METHODS: Thirty-two CFpatients (15 males) with mean age 9.90 (range: 2-23) years, performed spirometry and multiple breath washout (MBW) before and one month after IV antibiotic treatment. Nineteen patients received a course of elective treatment (group A) and 13 received IV antibiotic regimens for an acute exacerbation (group B). RESULTS: Statistically significant differences after treatment were seen in LCI (p≤0.001), and Forced Expiratory Flow (FEF) z-scores (p<0.05). FEV1 did not change significantly after drug intervention. Dividing patients into two groups, only LCI showed significant change (p<0.05), when treatment was administered on a regular basis. Patients being treated for an acute pulmonary exacerbation showed significant improvement in most of the lung function parameters: LCI (p=0.0001), FEV1% (p=0.05), FEV1 z-score (p=0.033) and FEF25-75 (p=0.046). The mean LCI difference was significantly greater in group B compared to group A (p=0.001). CONCLUSION:LCI is more sensitive marker than FEV1 to assess the effect of IV antibiotic treatment among CFchildren. IV antibiotics are more effective on lung function parameters, when they are administered for an acute exacerbation, than when they are given on a regular basis. Hippokratia 2015, 19 (1): 47-52.
Authors: H Eigen; H Bieler; D Grant; K Christoph; D Terrill; D K Heilman; W T Ambrosius; R S Tepper Journal: Am J Respir Crit Care Med Date: 2001-03 Impact factor: 21.405
Authors: Paul D Robinson; Philipp Latzin; Sylvia Verbanck; Graham L Hall; Alexander Horsley; Monika Gappa; Cindy Thamrin; Hubertus G M Arets; Paul Aurora; Susanne I Fuchs; Gregory G King; Sooky Lum; Kenneth Macleod; Manuel Paiva; Jane J Pillow; Sarath Ranganathan; Sarah Ranganathan; Felix Ratjen; Florian Singer; Samatha Sonnappa; Janet Stocks; Padmaja Subbarao; Bruce R Thompson; Per M Gustafsson Journal: Eur Respir J Date: 2013-02-08 Impact factor: 16.671
Authors: J S Elborn; R J Prescott; B H Stack; M C Goodchild; J Bates; C Pantin; N Ali; D J Shale; M Crane Journal: Thorax Date: 2000-05 Impact factor: 9.139
Authors: Pim A de Jong; Yasutaka Nakano; Wim C Hop; Frederick R Long; Harvey O Coxson; Peter D Paré; Harm A Tiddens Journal: Am J Respir Crit Care Med Date: 2005-04-14 Impact factor: 21.405
Authors: Richard Kraemer; Andrea Blum; Andreas Schibler; Roland A Ammann; Sabina Gallati Journal: Am J Respir Crit Care Med Date: 2004-11-05 Impact factor: 21.405
Authors: R Amin; P Subbarao; W Lou; A Jabar; S Balkovec; R Jensen; S Kerrigan; P Gustafsson; F Ratjen Journal: Eur Respir J Date: 2010-08-06 Impact factor: 16.671
Authors: Jane Davies; Helen Sheridan; Nicholas Bell; Steve Cunningham; Stephanie D Davis; J Stuart Elborn; Carlos E Milla; Timothy D Starner; Daniel J Weiner; Po-Shun Lee; Felix Ratjen Journal: Lancet Respir Med Date: 2013-09-10 Impact factor: 30.700
Authors: Wanda J Kozlowska; Andrew Bush; Angela Wade; Paul Aurora; Siobhán B Carr; Rosie A Castle; Ah-Fong Hoo; Sooky Lum; John Price; Sarath Ranganathan; Clare Saunders; Sanja Stanojevic; John Stroobant; Colin Wallis; Janet Stocks Journal: Am J Respir Crit Care Med Date: 2008-04-10 Impact factor: 21.405